文献速递银屑病与炎症性皮肤病

银屑病治疗中的生物类似药:临床试验与观察性研究的系统综述

Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
PubMed 文献 · JAMA Dermatol · 2023-01-01

该系统综述检索了MEDLINE、EMBASE、Cochrane图书馆、ClinicalTrials.gov和欧盟临床试验注册库,纳入14项试验和3项队列研究,比较生物类似药与原研生物制剂治疗银屑病的疗效和安全性。结果显示,在第16周和第52周,达到PASI 75改善率和不良事件风险在比较组间无临床或统计学显著差异。多数证据基于随机临床试验,但缺乏高质量真实世界证据,未来需研究长期疗效和安全性。

要点

  • 生物类似药与原研药在PASI 75应答率和不良事件风险上无临床或统计学显著差异。
  • 14项试验中3项低偏倚风险,11项中等偏倚风险;所有队列研究为中等至高度偏倚风险。
  • 缺乏高质量真实世界证据,需未来研究长期疗效和安全性。

核心结论

  • 生物类似药与原研药治疗银屑病的疗效和安全性无临床或统计学显著差异。

研究设计与样本

  • 系统综述纳入14项试验(10项阿达木单抗、2项依那西普、1项英夫利西单抗、1项乌司奴单抗)和3项队列研究(1项阿达木单抗、1项依那西普、1项英夫利西单抗和依那西普)。
  • 检索MEDLINE、EMBASE、Cochrane图书馆、ClinicalTrials.gov和欧盟临床试验注册库于2022年8月进行,分析于2022年9月至11月进行。

主要发现

  • 12项试验在未使用过原研药的患者中比较生物类似药与原研药,11项试验比较从原研药转换至生物类似药与持续原研药治疗。
  • 第16周和第52周达到PASI 75改善率和不良事件风险在比较组间无临床或统计学显著差异。
  • 2项队列研究显示原研药与生物类似药在有效性和安全性结局上无差异,而1项研究报告转换至阿达木单抗生物类似药的患者在12个月时不良事件更多。
  • 3项试验显示低偏倚风险,11项试验为中等偏倚风险;所有队列研究为中等至高度偏倚风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 缺乏高质量真实世界证据。
  • 未来研究需检查生物类似药治疗银屑病的长期疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Biosimilars have the potential to reduce costs for the management of moderate-to-severe psoriasis compared with originators. However, the extrapolation of evidence enables the approval of a biosimilar for use in indications held by the originator without directly being studied in clinical trials. Thus, biosimilars can be approved for psoriasis based on extrapolated evidence from other diseases. The availability of evidence for the effectiveness and safety of biosimilars for the treatment of psoriasis is therefore unclear. OBJECTIVE: To compare the efficacy/effectiveness and safety of biosimilars with originator biologics for the treatment of patients with psoriasis. EVIDENCE REVIEW: MEDLINE, EMBASE, Cochrane Library, ClinicalTrials.gov, and The European Union Clinical Trials Register were searched in August 2022. Eligible studies were appraised using the Cochrane Risk of Bias 2 and ROBINS-I tools. All analyses were conducted from September 2022 to November 2022. FINDINGS: Fourteen trials (10 adalimumab, 2 etanercept, 1 infliximab, and 1 ustekinumab) and 3 cohort studies (1 adalimumab, 1 etanercept, 1 infliximab and etanercept) were included. Twelve trials compared biosimilars with originators in originator-naive patients (starters), and 11 trials compared switching from originator to biosimilar (switchers) with continuous originator treatments. There was no clinically or statistically significant difference in rates of achieving 75% improvement in Psoriasis Area and Severity Index scores and risks of adverse events (AEs) at week 16 and week 52 between the comparators. Two cohort studies showed no difference in effectiveness and safety outcomes between originators and biosimilars, whereas 1 study reported more AEs in patients who switched to biosimilars of adalimumab at 12 months. Three trials showed low risk of bias, whereas 11 trials had moderate risk of bias. All cohort studies had moderate to high risk of bias. CONCLUSIONS AND RELEVANCE: In this systematic review, there was no clinically or statistically significant difference in the efficacy and safety between biosimilars and originators for the treatment of patients with psoriasis. Most of the available evidence was based on randomized clinical trials, although high-quality real-world evidence was lacking. Future studies are needed to examine the long-term effectiveness and safety of biosimilars for the treatment of patients with psoriasis.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Phan DB, Elyoussfi S, Stevenson M, et al. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies. JAMA Dermatol. 2023. PMID: 37256582. doi:10.1001/jamadermatol.2023.1338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。